p53与消化系统恶性肿瘤的研究进展

doi:10.11904/j.issn.1002-3070.2016.05.017

摘要/Abstract

摘要： p53作为目前广泛研究的肿瘤抑制基因,在调节细胞周期、修复损伤DNA、清除自由基、调控免疫反应等过程中均起重要作用。目前研究发现,p53突变与50%以上消化系统恶性肿瘤的发生、发展、浸润和转移等生物学行为密切相关。鉴于目前的研究发现,本文对p53的生物学特性、p53与消化系统恶性肿瘤的关系及基因治疗进行综述,希望为消化系统恶性肿瘤的发病机制、诊治及预后提供参考。

关键词: p53, 突变, 消化系统恶性肿瘤, 基因治疗

Abstract: p53,the widely studied tumor suppressor gene,plays a key role in regulating cell cycle,repairing DNA damages,eliminating free radicals and regulating immune responses and so on.The recent studies showed that p53 mutation was in close biological connections with the occurrence,development,infiltration and metastasis in over 50 percent digestive systemic malignant tumors.In view of the current researches,we review the biological features of p53,the relationship between p53 and digestive systemic malignant tumors,and gene therapy of p53 to provide references for the pathogenesis,diagnosis,treatment and prognosis of digestive systemic malignant tumors in this paper.

Key words: p53, Mutation, Digestive systemic malignant tumors, Gene therapy

中图分类号:

R73.5

王鹏综述, 王征, 周志祥审校. p53与消化系统恶性肿瘤的研究进展[J]. 实用肿瘤学杂志, 2016, 30(5): 468-472.

WANG Peng, WANG Zheng, ZHOU Zhixiang. Roles of p53 in the interaction with digestive malignant tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 468-472.

参考文献

1 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
2 Li T,Kon N,Jiang L,et al.Tumor suppression in the absence of p53-mediated cell-cycle arrest,apoptosis,and senescence[J].Cell,2012,149(6):1269-1283.
3 苏明慧,王大成.p53基因的研究进展[J].内蒙古医学杂志,2011,43(19):46-49.
4 Momand J,Wu HH,Dasgupta G.MDM2—master regulator of the p53 tumor suppressor protein[J].Gene,2000,242(1/2):15-29.
5 Grossman SR,Deato ME,Brignone C,et al.Polyubiquitination of p53 by a ubiquitin ligase activity of p300[J].Science,2003,300(5617):342-344.
6 Takagi M,Absalon MJ,Mclure KG,et al.Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin[J].Cell,2005,123(1):49-63.
7 Karim S,Ali A.Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India[J].World J Gastroenterol,2009,15(11):1381-1387.
8 Song H,Hollstein M,Xu Y.p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM[J].Nat Cell Biol,2007,9(5):573-580.
9 Wei W,Wang Y,Yu X,et al.Expression of TP53,BCL-2,and VEGFA genes in esophagus carcinoma and its biological significance[J].Med Sci Monit,2015,21(3):3016-3022.
10 Yao W,Qin X,Qi B,et al.Association of p53 expression with prognosis in patients with esophageal squamous cell carcinoma[J].Int J Clin Exp Pathol,2014,7(10):7158-7163.
11 Li S,Li J,Liu Z,et al.Predictive value of P53,Ki-67,HER2 protein detection in neoadjuvant chemotherapy for adenocarcinoma of gastroesophageal junction[J].Zhonghua Wei Chang Wai Ke Za Zhi,2015,18(9):901-904.
12 Busuttil RA,Zapparoli GV,Haupt S,et al.Role of p53 in the progression of gastric cancer[J].Oncotarget,2014,5(23):12016-12026.
13 Wei K,Jiang L,Wei Y,et al.The prognostic significance of p53 expression in gastric cancer:a meta-analysis[J].J Cancer Res Clin Oncol,2015,141(4):735-748.
14 Babacan NA,Egilmez HR,Yucel B,et al.The prognostic value of UHRF-1 and p53 in gastric cancer[J].Saudi J Gastroenterol,2016,22(1):25-29.
15 Calik M,Demirci E,Altun E,et al.Clinicopathological importance of Ki-67,p27,and p53 expression in gastric cancer[J].Turk J Med Sci,2015,45(1):118-128.
16 Yan WF,Wu G,Sun PC,et al.P53 mutations occur more commonly than KRAS mutations in colorectal adenoma[J].Int J Clin Exp Med,2015,8(1):1370-1375.
17 Horvath B,Liu G,Wu X,et al.Overexpression of p53 predicts colorectal neoplasia risk in patients with inflammatory bowel disease and mucosa changes indefinite for dysplasia[J].Gastroenterol Rep(Oxf),2015,3(4):344-349.
18 Cooks T,Pateras IS,Tarcic O,et al.Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer[J].Cancer Cell,2013,23(5):634-646.
19 Iwamuro M,Kawai Y,Matsumoto T,et al.Serum anti-p53 antibody as a tumour marker for colorectal cancer screening[J].Ecancermedicalscience,2015,9(3):560-571.
20 Dong C,Zhao B,Long F,et al.Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein[J].Oncotarget,2016,7(8):8850-8865.
21 Chen J,Wang H,Wang J,et al.STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7[J].Cancer Cell Int,2015,15:111.
22 Gomes AR,Abrantes AM,Brito AF,et al.Influence of P53 on the radiotherapy response of hepatocellular carcinoma[J].Clin Mol Hepatol,2015,21(3):257-267.
23 Ghosh M,Sakhuja P,Singh S,et al.p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer[J].Saudi J Gastroenterol,2013,19(1):34-39.
24 Cai W,Li Q,Yang Z,et al.Expression of p53 upregulated modulator of apoptosis(PUMA)and C-myb in gallbladder adenocarcinoma and their pathological significance[J].Clin Transl Oncol,2013,15(10):818-824.
25 Kim K,Kim DH,Chae SW,et al.Expression of cell cycle-related proteins,p16,p53 and p63 as important prognostic markers in gallbladder adenocarcinoma[J].Pathol Oncol Res,2014,20(2):409-415.
26 Kim H,Park CY,Lee JH,et al.Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer[J].Ann Surg Treat Res,2015,88(4):200-207.
27 Kurahara H,Maemura K,Mataki Y,et al.Impact of p53 and PDGFR-beta expression on metastasis and prognosis of patients with pancreatic cancer[J].World J Surg,2016,40(8):1977-1984.
28 Xiang JF,Wang WQ,Liu L,et al.Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9≥1,000 U/mL[J].Sci Rep,2016,6:19222.
29 Guan YS,Liu Y,He Q,et al.p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC:one-year follow-up[J].World J Gastroenterol,2011,17(16):2143-2149.
30 Yang ZX,Wang D,Wang G,et al.Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma[J].J Cancer Res Clin Oncol,2010,136(4):625-630.

[1]	施俊, 倪小兵, 毛敏, 彭兴春. Nultin-3联合顺铂对口腔鳞状细胞癌细胞的抑制作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 488-492.
[2]	贺伟, 母齐鸣, 王刚, 万波, 廖波, 杨娟. TACC3和p53蛋白在原发性肝癌组织中的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 420-425.
[3]	梁冠盈, 迟秋君, 李晓梅. 伏立诺他对卵巢癌SKOV3细胞增殖和凋亡的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(4): 298-302.
[4]	闫石, 霍明鸣, 庞慧, 李焱, 蔡莉. p53对绝经后HR阳性、HER-2阳性术后乳腺癌患者内分泌药物疗效的预测价值[J]. 实用肿瘤学杂志, 2018, 32(3): 234-213.
[5]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[6]	陈琢, 孔艺然. 沉默UHRF1对乳腺癌细胞增殖和转移的影响[J]. 实用肿瘤学杂志, 2017, 31(6): 512-518.
[7]	王治国, 武晓丹, 战莹, 张彤, 张国旭. 甲状腺乳头状癌¹⁸F-FDG PET/CT显像葡萄糖代谢与BRAF突变的相关性研究[J]. 实用肿瘤学杂志, 2017, 31(6): 519-523.
[8]	邢琦, 张倩综述, 乔文波审校. 放射性肺损伤相关细胞因子及防治的研究进展[J]. 实用肿瘤学杂志, 2015, 29(3): 250-253.
[9]	徐延斌(综述),李建华(审校). 放射性粒子治疗与基因治疗神经胶质瘤的概况[J]. 实用肿瘤学杂志, 2015, 29(2): 153-156.
[10]	刘冰梅, 杨晶, 张翰文, 邢荣贵, 李丽丽, 赵丽萍, 乔适, 尤海燕. 角化棘皮瘤与高分化鳞状细胞癌细胞周期和细胞凋亡相关蛋白表达的研究[J]. 实用肿瘤学杂志, 2014, 28(6): 485-491.
[11]	徐睿瑞, 温荔媛, 孙国强, 孟庆威, 孙立春, 蔡莉. Caveolin-1的表达与EGFR突变在NSCLC中的相关性及其临床意义的研究[J]. 实用肿瘤学杂志, 2014, 28(6): 498-502.
[12]	宋春雨综述曲国蕃审校. 骨肉瘤基因治疗靶点研究的新进展[J]. 实用肿瘤学杂志, 2014, 28(4): 364-366.
[13]	肖芹, 顾学文, 田秀春, 王翠梅. p53和表皮生长因子受体在胃癌中的表达及其临床病理意义[J]. 实用肿瘤学杂志, 2012, 26(6): 532-539.
[14]	程文, 邵华, 李洁冰, 杨先, 张国强, 申宝忠, 耿敬姝. 造影剂微泡介导WT-p53基因靶向治疗肝癌的实验研究[J]. 实用肿瘤学杂志, 2012, 26(4): 298-301.
[15]	苏君, 张学新, 常亮, 张锐, 金华, 张磊, 王洪滨. p53、MDM2在低级别胶质瘤复发、恶变中的变化及意义[J]. 实用肿瘤学杂志, 2012, 26(4): 311-313.